Back to search results

FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Ras-mutated Metastatic Colorectal Cancer · mCRC · MSS Metastatic Colorectal Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Central Alabama Research, Homewood, Alabama, United States

  • Clinical Research Advisors (Beverly Hills), Beverly Hills, California, United States

  • Clinical Research Advisors (Encino), Encino, California, United States

  • Clinical Research Advisors (Korea Town), Koreatown, California, United States

  • Clinical Research Advisors (Downtown LA), Los Angeles, California, United States

  • Clinical Research Advisors (West Hollywood), Los Angeles, California, United States

  • Clinical Research Advisors (West Covina), West Covina, California, United States

  • Emory Winship Cancer Institute, Atlanta, Georgia, United States

  • Community Health Network, Indianapolis, Indiana, United States

  • Washington University School of Medicine, St Louis, Missouri, United States

  • Summit Health Cancer Center, Florham Park, New Jersey, United States

  • Rutgers Cancer Institute, New Brunswick, New Jersey, United States

  • Gabrail Cancer Center, Canton, Ohio, United States

View source on ClinicalTrials.gov(opens in a new tab)